AMGN Jun 2025 260.000 put

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

14.05

-0.35

(-2.43%)

At close: 11:40AM EDT

Loading interactive chart...

PR Newswire
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
Zacks
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
Investor's Business Daily
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.